State pharmacy boards and peptides: where states diverge from the FDA

Two layers of rules

Peptide compounding sits under two layers of law. The federal layer, section 503A of the Food, Drug, and Cosmetic Act, decides which bulk ingredients a pharmacy may use: one with a USP or National Formulary monograph, a component of an FDA-approved drug, or a substance on FDA's 503A list (statute) ¹. Most popular peptides meet none of those, which is why our guide to the 503A list matters so much for them.

The state layer licenses everyone in the chain: the pharmacy, the clinic that buys and stores drugs, the doctor, nurse practitioner or physician assistant who prescribes. A state cannot make a federally ineligible ingredient lawful to compound, but it can discipline its own licensees, set conditions on licences, and issue guidance on how it reads the law. That is where states have started to diverge, and it is why searches for 'peptide laws by state' have no single answer. The same vial can carry very different professional consequences for the clinician supplying it depending on which state's board licenses them.

This article sticks to what we could verify. For each state below we read the board's or legislature's own document; reports about other states that we could not confirm in a primary source are left out.

Ohio: suspensions, a revocation and plain guidance

Ohio's Board of Pharmacy has been the most active board we found. In guidance updated on December 8, 2025, it said that since the start of 2025 it had summarily suspended more than 30 clinics and medical spas after finding clear and convincing evidence that they posed a danger of immediate and serious harm. The same guidance states that peptides such as BPC-157, and other bulk substances in FDA's Categories 2 and 3, cannot be compounded because doing so violates federal and state law, and that peptide injections not approved by the FDA fall under its warning about non-approved drugs (state board guidance) ².

One case shows what that looks like. After an inspection on July 23, 2025, the board summarily suspended the dangerous-drug distributor licence of a Cincinnati cryotherapy and wellness business on August 6, 2025. Its findings listed vials of a BPC-157 and TB-500 blend and a product combining GHK-Cu, BPC-157 and TB-500, alongside other violations including foreign-sourced injectables and expired and adulterated drugs in active stock. The board's order, mailed and effective October 23, 2025, permanently revoked the licence and imposed a $90,000 fine (state board order) ³.

Ohio's approach is to treat unapproved peptides found in a clinic as one of many signs of an unsafe drug operation, and to act on the clinic's licence rather than wait for federal enforcement.

Louisiana: a law that sounds like an opening

Louisiana went the other way in tone. Act 374 of 2026, from Senate Bill 253, was signed on May 22, 2026, and took effect on August 1, 2026. It bars any professional or occupational licensing board from prohibiting a prescriber from providing patients with peptides shipped from an FDA-registered 503B outsourcing facility or a 503A compounding pharmacy, and bars boards from prohibiting a Louisiana pharmacist in a state-permitted pharmacy from compounding and dispensing peptides (state law) ⁴.

The conditions are what matter. Each protection applies only when the facility or pharmacist is in compliance with the federal compounding statutes, 21 U.S.C. 353a or 353b, and the applicable USP-NF chapters (state law) ⁴. An earlier version of the bill would have let pharmacies compound a peptide once it left FDA's Category 2 list; the enacted text replaced that with the federal-compliance requirement (bill text) ⁵. Because federal law still does not let a 503A pharmacy compound BPC-157 or most other popular peptides, the Act stops Louisiana boards from banning compliant peptide prescribing and compounding, but does not create a route for ingredients federal law excludes.

In practice, Act 374 protects compounded peptides that are already federally lawful, and would protect more if FDA adds peptides to the 503A list.

Mississippi: three boards, one statement

On August 19, 2026, Mississippi's Board of Nursing, Board of Pharmacy and State Board of Medical Licensure jointly issued a statement on non-FDA-approved, research-grade peptides. It says these products have not been tested, reviewed or found safe or effective for human use, that neither provider nor patient can verify the contents of a vial, and that under no circumstances may a health care provider compound, administer or dispense a research-grade peptide to a patient. It extends that prohibition to advising, recommending, supplying, prescribing and administering, and says providers cannot get around it by delegating to others (joint board statement) ⁶.

The statement adds two practical points. Providers must buy all prescription products and ingredients from entities permitted by the Mississippi Board of Pharmacy, and labelling a product research-grade does not reduce a provider's professional or legal liability. It also distinguishes patients who obtain and use research peptides on their own, which it treats as the patient's risk, from any involvement by a licensed professional, which it treats as the practice of medicine and prohibits (joint board statement) ⁶.

Alabama: the medical board's notice

Alabama's action came from its Board of Medical Examiners and Medical Licensure Commission rather than the pharmacy board, in a notice whose issuance Reuters reported on May 26, 2026. It states that research-grade peptides are not FDA-approved or tested for human use, that physicians must buy prescription products and ingredients only from entities permitted by the Alabama State Board of Pharmacy, and that under no circumstances may a physician compound, administer or dispense a non-FDA-approved or research-grade peptide, including advising, recommending, supplying or prescribing one (state board notice) ⁷.

It closes a common workaround: nurse midwives, nurse practitioners and physician assistants may prescribe only drugs on an approved formulary, and no research-grade or unapproved peptide is on one, so they cannot prescribe or administer them either. Patient consent forms calling a product research-grade are, in the board's words, ineffective at removing liability (state board notice) ⁷. Mississippi's later statement uses closely matching language.

Why boards are acting now

The documents give their own reasons. Ohio's guidance frames peptides within a broader pattern its inspectors kept finding at clinics and medical spas: drugs bought outside legitimate supply chains, foreign-labelled products and compounding without the required controls, which it says led to more than 30 summary suspensions in 2025 (state board guidance) ². Mississippi's and Alabama's statements centre on verification: because research-grade products are outside FDA oversight, neither the clinician nor the patient can know what a vial contains, so a licensed professional cannot meet the standard of care by using one (joint board statement) ⁶.

The timing also tracks the federal picture. FDA's April 2026 removal of twelve peptides from Category 2 and the July 2026 advisory votes were often described online as if they legalised these peptides. Alabama's notice came in May, between the two federal steps, and Mississippi's in August, a month after the votes; both restate that nothing had changed for research-grade products, whatever happens to compounding.

How the four compare

• Ohio (Board of Pharmacy): licence suspensions since early 2025 and at least one permanent revocation with a $90,000 fine (October 2025); guidance that BPC-157 and Category 2 and 3 substances cannot be compounded. Restrictive, enforced.
• Louisiana (legislature): Act 374 bars boards from prohibiting peptide prescribing and compounding, but only where federal compounding law is met. Permissive in tone, federally bounded in effect.
• Mississippi (three boards): joint statement barring licensed providers from any involvement with research-grade peptides; licensed sourcing required. Restrictive, policy statement.
• Alabama (medical board): notice barring physicians, PAs, CRNPs and CNMs from research-grade peptides; consent forms ineffective. Restrictive, policy statement.

Three of the four are aimed at the professionals they license and at 'research-grade' products in particular. None addresses an individual buying peptides for personal use, which Mississippi explicitly leaves as the patient's own risk (joint board statement) ⁶.

What 'diverge from the FDA' really means

The phrase suggests states are loosening or tightening federal rules. In practice the four actions above do something narrower. The restrictive states are using licensing powers the federal government does not have, to discipline clinics and clinicians who use products that were never lawful under federal law. Louisiana's law limits what its own boards may forbid, while expressly deferring to the federal compounding statutes (state law) ⁴.

So a patient in Louisiana cannot obtain lawfully compounded BPC-157 any more than one in Ohio, because the federal ingredient rule applies in both. What differs is the risk to the clinician and the clinic: in Ohio, Mississippi and Alabama, a licensed professional found supplying research-grade peptides faces board action under published guidance. Our BPC-157 prescription article and category guide cover the federal side.

What we left out, and why

Searching for state peptide laws turns up many confident claims: that particular states let pharmacies compound peptides freely, that others have banned specific compounds outright, or that boards have disciplined clinicians in states we have not listed. Some may be true. We could not confirm them in a board order, a board statement or a statute, so they are not in this article. Several of the claims we found came from businesses that sell peptides or compounded products, which is another reason to check the primary source.

If your state is not listed, that is not evidence that it has no rules. Every state licenses pharmacies and prescribers, and federal compounding law applies everywhere. The quickest check is your state board of pharmacy's and medical board's news or guidance pages, and the license-verification tool for any pharmacy you are considering.

How to check your own state

1. Your state board of pharmacy. Look for news, newsletters or guidance on compounding, peptides, GLP-1 drugs or 'research use only' products, and for published disciplinary orders.
2. Your state medical and nursing boards. Restrictions on prescribers often come from these boards, as in Alabama and Mississippi, not from the pharmacy board.
3. Your legislature's bill search. Search for 'peptide' in the current session; check whether a bill passed and read the enacted text, because, as Louisiana shows, amendments can change what a bill does.
4. The licence lookup. Before using any pharmacy or clinic, confirm its licence or permit in your state.

When you find a claim about your state's law, look for the document behind it: a statute number, a board order with a case number, or a dated board statement. Without one, treat the claim as unverified.

What this means for patients

For someone considering peptides, the state picture adds one clear lesson: a clinician offering research-grade peptides is, in a growing number of states, acting against published board positions, and a consent form does not change that (state board notice) ⁷. A legitimate provider can explain where a prescribed peptide comes from, which licensed pharmacy compounds or dispenses it, and why it is lawful. Our guide to legitimate prescriptions sets out how to check.

For approved peptide drugs, such as GLP-1 medicines, none of the state actions above changes access; they are aimed at unapproved and research-grade products. If a clinic tells you a state law now allows it to supply BPC-157 or similar peptides, ask which statute or board order it means, then read it: as Louisiana's Act shows, the text may say something narrower.

What this means for clinicians and pharmacies

For licensed professionals the documents are direct. Ohio's guidance names BPC-157 and Category 2 and 3 substances as not compoundable and has backed that with suspensions (state board guidance) ². Mississippi and Alabama prohibit recommending, supplying, prescribing or administering research-grade peptides and require buying from board-permitted sources (joint board statement) ⁶. Louisiana's Act 374 protects only compounding and prescribing that meets federal law (state law) ⁴.

None of this is legal advice, and boards can and do update guidance. Our regulatory tracker follows federal status, and our country pages cover rules outside the US.

What to watch next

The biggest change for every state would come from Washington: if FDA adds any of the six peptides its advisers backed in July 2026 to the 503A list, Louisiana's Act 374 would immediately protect compliant compounding of them there, and boards elsewhere would have to revisit guidance written on the premise that they cannot be compounded. Our report on the July votes tracks that decision.

At the state level, joint statements like Mississippi's, which bring medical, nursing and pharmacy boards together, are worth watching because they close gaps between professions. So are bills modelled on Louisiana's, which may differ in whether they keep its federal-compliance condition.

How it adds up (as of October 4, 2026)

Federal law decides which peptides a pharmacy may compound; states license the people and businesses involved. Ohio's Board of Pharmacy has suspended more than 30 clinics and med spas since early 2025 and revoked at least one licence where BPC-157 and TB-500 vials were found. Mississippi's three boards and Alabama's medical board bar licensed providers from any involvement with research-grade peptides. Louisiana's Act 374 stops boards from banning peptide prescribing and compounding, but only where federal compounding law is met. None of these actions makes an unapproved peptide lawful to compound.

Frequently asked questions

Are peptides legal in my state?

Approved peptide drugs are legal everywhere with a prescription. Compounding unapproved peptides is limited by federal law in every state, and some states, including Ohio, Mississippi and Alabama, have added board actions against licensed providers using research-grade peptides.

Did Louisiana legalize peptides?

Act 374 (effective August 1, 2026) stops licensing boards from prohibiting peptide prescribing and compounding, but only when the pharmacy complies with federal compounding law, which still excludes BPC-157 and most popular peptides.

What did Ohio do about peptides?

Its Board of Pharmacy says BPC-157 and other Category 2 and 3 substances cannot be compounded, reports suspending more than 30 clinics and med spas since early 2025, and revoked one clinic's licence with a $90,000 fine in October 2025.

Can a doctor in Mississippi or Alabama prescribe research peptides?

No. Mississippi's joint board statement (August 19, 2026) and Alabama's medical board notice (May 2026) bar licensed providers from prescribing, recommending or administering research-grade peptides, and consent forms do not remove liability.

Can a state allow compounding that federal law forbids?

No. A state can restrict its own licensees further, but cannot make a federally ineligible ingredient lawful to compound.

Related on Grey Peptides

• How a substance gets on the 503A list
• Can a doctor prescribe BPC-157?
• Legitimate prescriptions and red flags
• Regulatory tracker

Sources

1. 21 U.S.C. 353a (Federal Food, Drug, and Cosmetic Act section 503A), subsection (b)(1)(A)(i); text read October 4, 2026.
2. Ohio Board of Pharmacy. Ten Common Prescriber Clinic and Medical Spa Violations (guidance, updated December 8, 2025); read October 4, 2026.
3. Ohio Board of Pharmacy. Order in the Matter of CryoOH dba Cryo Ohio Inc., Case No. A-2025-0227 (summary suspension August 6, 2025; order mailed and effective October 23, 2025); read October 4, 2026.
4. Louisiana Legislature. Act No. 374 of the 2026 Regular Session (Senate Bill 253, Sen. McMath), enacting R.S. 37:23.5, signed May 22, 2026, effective August 1, 2026; enrolled text read October 4, 2026.
5. Louisiana Legislature. Senate Bill 253 (2026 Regular Session), engrossed version (SLS 26RS-509), with Senate Health and Welfare Committee amendment; read October 4, 2026.
6. Mississippi Board of Nursing, Mississippi Board of Pharmacy and Mississippi State Board of Medical Licensure. Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides, jointly issued August 19, 2026; read October 4, 2026.
7. Alabama Board of Medical Examiners and Medical Licensure Commission. Board Issues Official Notice Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides (press release; issuance reported by Reuters on May 26, 2026); read October 4, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.